pause button on blue background
Biotech

Intellia pauses phase 3 CRISPR trials after patient hospitalized

Intellia Therapeutics has temporarily paused dosing and screening in a pair of phase 3 trials in response to a liver safety signal.
Nick Paul Taylor Oct 27, 2025 9:45am
GeminiGeneratedImagewmbtpzwmbtpzwmbtpng

First FDA IND Milestone Using Human Vascularized Organoid Data

Oct 27, 2025 8:00am
graphic of a larger shark chomping up a smaller one

Cardiometabolic field drives M&A while cancer deals drop: report

Oct 27, 2025 2:39pm
GettyImages-1494029118jpg

iRegene's Scalable Tech Unlocks Commercial Cell Therapies

Oct 27, 2025 8:00am
NVS

Novartis pays $12B for late-stage dystrophy biotech Avidity

Oct 26, 2025 4:01pm
De-Risking Clinical Development Strategic Multipliers in Global Trials

De-Risking Clinical Development: Strategic Multipliers in Global Trials

Oct 27, 2025 8:00am
More News

Zenas autoimmune drug prompts 95% drop in lesions in MS study

Oct 27, 2025 9:25am

BridgeBio aces phase 3 rare disease test, clearing path to FDA

Oct 27, 2025 7:00am

MapLight goes public via $250M IPO to fund Cobenfy competitor

Oct 27, 2025 6:45am

Hemab raises $157M series C for rare bleeding disorder goals

Oct 27, 2025 6:00am